Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells.
The effects of the production of two closely related cytokines, oncostatin M (OSM) and leukaemia inhibitory factor (LIF), by astrocytoma cells were investigated using the stable cell line human U373-MG, which expressed and secreted both biologically active polypeptides. The expression of LIF by these cells caused resistance to this cytokine due to loss of the LIF receptor (LIFR), from the cell surface, suggesting its retention. In contrast, cells expressing OSM were stimulated by this cytokine, utilizing an autocrine mechanism, and possessed receptors for OSM, but not LIF, on the cell surface. In these cells the continuous up-regulation of OSM-induced gene expression was found even though the Janus kinase-signal transducer and activator of transcription ('JAK/STAT') pathway was almost exhausted due to long-term autocrine stimulation of the cells by OSM. The amount of LIFR was down-regulated in both LIF- and OSM-producing cells and this effect was not found in wild-type U373-MG cells treated with externally added cytokines. To investigate the mechanism of autocrine stimulation by OSM we constructed a stable cell line expressing a form of OSM that is retained in the endoplasmic reticulum (ER). This biologically active cytokine was not secreted, but was localized in the ER. In addition, it did not stimulate the astrocytoma cells in an autocrine manner. We conclude that expression of LIF causes resistance of astrocytoma cells to this cytokine, whereas expression of OSM leads to autocrine stimulation.
Kasza
A
A
Department of Animal Biochemistry, Institute of Molecular Biology, Jagiellonian University, 31-120 Krakow, Poland.
Rogowski
K
K
Kilarski
W
W
Sobota
R
R
Bernas
T
T
Dobrucki
J
J
Travis
J
J
Koj
A
A
Bugno
M
M
Kordula
T
T
D015703:Antigens, CD / Q000378:metabolism; D001254:Astrocytoma / Q000378:metabolism* / Q000473:pathology; D001483:Base Sequence; D050822:Cytokine Receptor gp130; D017931:DNA Primers; D004721:Endoplasmic Reticulum / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006131:Growth Inhibitors / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D015850:Interleukin-6; D053613:Janus Kinase 1; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008222:Lymphokines / Q000378:metabolism* / Q000502:physiology; D008562:Membrane Glycoproteins / Q000378:metabolism; D053683:Oncostatin M; D010455:Peptides / Q000378:metabolism* / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D018121:Receptors, Cytokine / Q000378:metabolism; D053606:Receptors, OSM-LIF; D014157:Transcription Factors / Q000378:metabolism; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; D017931:DNA Primers; D006131:Growth Inhibitors; C494199:IL6ST protein, human; D015850:Interleukin-6; C507837:LIF protein, human; C507840:LIFR protein, human; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008222:Lymphokines; D008562:Membrane Glycoproteins; C508351:OSM protein, human; D010455:Peptides; D018121:Receptors, Cytokine; D053606:Receptors, OSM-LIF; D014157:Transcription Factors; D053683:Oncostatin M; D050822:Cytokine Receptor gp130; D011505:Protein-Tyrosine Kinases; C507904:JAK1 protein, human; D053613:Janus Kinase 1